CLEO Advances Ovarian Cancer Detection with Strategic Partnership

CLEO Diagnostics Limited (ASX: COV) has announced a pivotal collaboration with Lindus Health to oversee the U.S. clinical trials of its innovative ovarian cancer blood test. This move marks a significant step towards gaining FDA approval. Chosen for its expertise in med-tech clinical trials, Lindus Health will manage the recruitment and study of up to 500 U.S. patients, aiming to validate the effectiveness of CLEO's test.

The study, set to commence next month, is a crucial component of CLEO's strategy to introduce its ovarian cancer detection technology to the U.S. market. Alongside, an Australian trial will run in parallel to ensure comprehensive data collection for FDA submission. CLEO's CEO, Richard Allman, highlighted the importance of this partnership in advancing their goal to enhance health outcomes for women facing ovarian cancer.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com